Snippet From Dr JJ Interview this Afternoon: : The most crucial difference between the average pharma company and us is that we are doing the clinical operations ourselves. We used a Contract Research Organization (CRO) for the electronic data capture backbone, but we are running all the trial aspects. The study coordinators know they are not talking to some executive who is doing their study today and another study tomorrow; they are talking to us directly.
The thing probably driving enrollment more than anything is that the study staff see patients getting better. We have published X-rays with patients with this white COVID-19 lung clearing in 48 to 96 hours. The study staff has not seen that before with COVID. There is nothing health professionals want more than to see their patients get better.
Robert Besthof: Our team is in close and continuous contact with the sites. When a site reaches out to us for something urgent, we respond, no matter if it is at night or on the weekends. COVID-19 does not pause, and neither do we. This is one element that distinguishes NeuroRx and has enabled us to progress this study so rapidly. If there are medical questions, we allow a rapid dialogue with a pulmonologist / critical care physician or a cardiologist / critical care physician, who support us in this study as consultants.
This vital communication with the sites also helps us prepare for potential challenges, such as the recent surge of hospital admissions that required rapid provisioning of additional drug supplies or maintaining communication continuity when some employees went on furlough.
We are very proud of having this level of trust and communication with our sites. Despite all the technology in this pandemic, the human element is critical.......
